LifeMD: An Overlooked GLP-1 Beneficiary

Company Overview - LifeMD (NASDAQ: LFMD) has a unique corporate structure, originally founded as ImmuDyne in 1994 and going public in 2001, later rebranding to Conversion Labs in 2018 before adopting its current name [1] Investment Approach - The investment strategy focuses on a holistic approach that incorporates both top-down and bottom-up valuation techniques, emphasizing the importance of detailed company aspects such as capital structure and debt covenants in equity valuation [1]